ATLANTA, Nov. 13 /PRNewswire/ -- CorMatrix Cardiovascular Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that the company was awarded the 2008 Frost & Sullivan Healthcare Innovation Award in the treatment of cardiovascular disease.
The award recognizes CorMatrix's contribution to the cardiovascular market through its involvement in the research, development and marketing of its ECM Technology(TM) for pericardial closure and cardiac tissue repair.
"Frost & Sullivan acknowledges CorMatrix's dedication in the development of the unique ECM Technology(TM). Through this unique technology the company strives to meet the ever growing demand and continuous innovation that characterizes the cardiac device market," said Frost & Sullivan industry analyst Archana Swathy. "This exceptional product enhances the patient's recovery after surgery by facilitating efficient tissue repair."
The company's ECM Technology(TM) product acts as a scaffold into which the patient's own cells migrate and integrate, stimulating the body's innate wound-healing mechanisms to repair tissue at the site of implantation. As the patient's cells populate the matrix, they lay down their own collagen, which matures over time to form a functional tissue repair. The implanted ECM material is gradually replaced and resorbed by the body as the patient's tissue is remodeled.
"We are honored to be presented with this Award, as the recognition further validates the increasing interest and acceptance that our ECM Technology(TM) continues to receive within the clinical community," commented Beecher Lewis, President and Chief Operating Officer of CorMatrix Cardiovascular.
The use of extracellular matrix technology in non-cardiovascular applications has established a significant foothold in soft tissue repair, wound management and orthopedic applications. Since the launch of CorMatrix's ECM for Pericardial Closure, the technology has been used at more than 220 hospitals across the U.S. and has been implanted in more than 9,000 cardiac procedures.
About CorMatrix ECM Technology(TM)
CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark to market its ECM Technology as an implant for pericardial closure, clearance in the U.S. for cardiac tissue repair, and is conducting preclinical studies on a number of cardiovascular applications including an emulsified, injectible form of its ECM Technology as a potential treatment for heart failure.
About CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative biomaterial devices that harness the body's own innate ability to regenerate damaged heart tissue. For more information visit http://www.cormatrix.com.
|SOURCE CorMatrix Cardiovascular Inc.|
Copyright©2008 PR Newswire.
All rights reserved